• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种筛查银屑病患者以使用生物制剂进行治疗的实用方法。

A practical approach to screening psoriasis patients for therapy with biologic agents.

出版信息

J Clin Aesthet Dermatol. 2008 Sep;1(3):50-4.

PMID:21203363
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3014311/
Abstract

The use of biologic agents for the treatment of psoriasis and psoriatic arthritis is increasingly growing among dermatologists. Proper screening is crucial to select patients who are appropriate candidates for these drugs. This article will outline a practical approach to evaluating patients, focusing on key aspects of the medical history, physical examination, and laboratory testing.

摘要

皮肤科医生越来越多地使用生物制剂来治疗银屑病和银屑病关节炎。进行适当的筛查对于选择适合使用这些药物的患者至关重要。本文将概述一种评估患者的实用方法，重点关注病史、体格检查和实验室检查的关键方面。

相似文献

1
A practical approach to screening psoriasis patients for therapy with biologic agents.一种筛查银屑病患者以使用生物制剂进行治疗的实用方法。
J Clin Aesthet Dermatol. 2008 Sep;1(3):50-4.
2
To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.是否进行检测？在使用全身性生物制剂治疗银屑病和银屑病关节炎时，对筛查和监测检测的价值进行了更新的基于证据的评估。
J Am Acad Dermatol. 2015 Sep;73(3):420-8.e1. doi: 10.1016/j.jaad.2015.06.004. Epub 2015 Jul 14.
3
To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis.检测还是不检测？对使用系统性生物制剂治疗银屑病时筛查和监测检测的价值进行循证评估。
J Am Acad Dermatol. 2008 Jun;58(6):970-7. doi: 10.1016/j.jaad.2008.03.004. Epub 2008 Apr 2.
4
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.阿普司特与生物制剂联合治疗作为银屑病关节炎和银屑病的安全选择
Curr Rheumatol Rev. 2019;15(3):234-237. doi: 10.2174/1573397115666181130094455.
5
Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.中重度银屑病和银屑病关节炎患者的生物治疗应用：临床环境中生物治疗使用情况的观察总结
J Cutan Med Surg. 2018 Nov/Dec;22(6):567-576. doi: 10.1177/1203475418786712. Epub 2018 Jun 28.
6
Psoriatic arthritis and psoriasis: need for a multidisciplinary approach.银屑病关节炎与银屑病：多学科治疗方法的必要性。
Semin Cutan Med Surg. 2005 Mar;24(1):46-51. doi: 10.1016/j.sder.2005.01.006.
7
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).阿达木单抗、乌司奴单抗和司库奇尤单抗在银屑病患者中的药物留存率：一项来自英国皮肤科医师协会生物制剂与免疫调节剂登记处（BADBIR）的前瞻性队列研究。
Br J Dermatol. 2020 Aug;183(2):294-302. doi: 10.1111/bjd.18981. Epub 2020 Mar 30.
8
Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: A nationwide, population-based observational study in Taiwan.2003年至2013年银屑病疾病的流行病学及当前治疗模式：台湾一项基于全国人群的观察性研究。
J Dermatol Sci. 2016 Dec;84(3):340-345. doi: 10.1016/j.jdermsci.2016.08.535. Epub 2016 Aug 25.
9
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.银屑病和银屑病关节炎管理中的医生观点：基于人群的银屑病和银屑病关节炎多国评估调查结果
J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2002-10. doi: 10.1111/jdv.13150. Epub 2015 Apr 16.
10
Psoriatic arthritis for dermatologists.皮肤科医生须知的银屑病关节炎
J Dermatolog Treat. 2020 Nov;31(7):662-679. doi: 10.1080/09546634.2019.1605142. Epub 2019 May 7.

引用本文的文献

1
Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures.肿瘤坏死因子-α（TNF-α）拮抗剂在慢性炎症性风湿病中的应用：风险及其最小化措施。
Curr Drug Saf. 2024;19(4):431-443. doi: 10.2174/0115748863274863231222023853.
2
Anti-tumor necrosis factor drug responses and skin-blood DNA methylation age: Relationships in moderate-to-severe psoriasis.抗肿瘤坏死因子药物反应与皮肤-血液 DNA 甲基化年龄：中重度银屑病中的关系。
Exp Dermatol. 2021 Aug;30(8):1197-1203. doi: 10.1111/exd.14207. Epub 2020 Oct 17.

本文引用的文献

1
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.国家银屑病基金会关于对接受系统治疗和生物制剂治疗的银屑病患者进行潜伏性结核感染筛查的共识声明。
J Am Acad Dermatol. 2008 Aug;59(2):209-17. doi: 10.1016/j.jaad.2008.03.023. Epub 2008 May 15.
2
Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient.在一名乙肝表面抗原阴性且乙肝表面抗体阳性的患者使用依那西普治疗期间发生乙肝病毒再激活。
Liver Int. 2008 May;28(5):718-20. doi: 10.1111/j.1478-3231.2007.01665.x.
3
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.银屑病和银屑病关节炎管理的护理指南：第1节。银屑病概述及生物制剂治疗银屑病的护理指南。
J Am Acad Dermatol. 2008 May;58(5):826-50. doi: 10.1016/j.jaad.2008.02.039.
4
To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis.检测还是不检测？对使用系统性生物制剂治疗银屑病时筛查和监测检测的价值进行循证评估。
J Am Acad Dermatol. 2008 Jun;58(6):970-7. doi: 10.1016/j.jaad.2008.03.004. Epub 2008 Apr 2.
5
Etanercept treatment for children and adolescents with plaque psoriasis.依那西普治疗儿童和青少年斑块状银屑病
N Engl J Med. 2008 Jan 17;358(3):241-51. doi: 10.1056/NEJMoa066886.
6
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.在患有风湿性疾病的HIV阳性个体中使用抗肿瘤坏死因子疗法。
Ann Rheum Dis. 2008 May;67(5):710-2. doi: 10.1136/ard.2007.081513. Epub 2007 Dec 13.
7
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.来自国家银屑病基金会医学委员会：接受生物制剂治疗的银屑病患者的监测与疫苗接种。
J Am Acad Dermatol. 2008 Jan;58(1):94-105. doi: 10.1016/j.jaad.2007.08.030. Epub 2007 Nov 5.
8
Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.肿瘤坏死因子靶向治疗诱发的自身免疫性疾病：233例分析
Medicine (Baltimore). 2007 Jul;86(4):242-251. doi: 10.1097/MD.0b013e3181441a68.
9
Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis.依那西普和英夫利昔单抗在类风湿关节炎患者中引起相同的血清学自身免疫改变。
Rheumatol Int. 2007 Nov;28(1):47-9. doi: 10.1007/s00296-007-0379-5. Epub 2007 Jun 13.
10
Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.聚乙二醇干扰素、利巴韦林和英夫利昔单抗成功治疗一名克罗恩病患者的慢性丙型肝炎。
Am J Gastroenterol. 2007 Jun;102(6):1333-4. doi: 10.1111/j.1572-0241.2007.01131.x.